Home | | | Search | | | Browse | | | Resources | | | Help | | | What's New | | | About |
---|
Infliximab in patients with chronic sarcoidosis with pulmonary involvement
This study is currently recruiting patients.
Sponsored by: | Centocor |
---|---|
Information provided by: | Centocor |
Purpose
Subjects eligible for this study will have a diagnosis of sarcoidosis for a least one year prior to screening and have evidence of disease on chest X-ray. Sarcoidosis must also have been proven by biopsy. Subjects must be taking a minimum of 10 mg prednisone (or equivalent dose of steroid) per day or one or more immunosuppressants (methotrexate, azathioprine, etc.) for at least the three month period immediately prior to screening.
Condition | Treatment or Intervention | Phase |
---|---|---|
Sarcoidosis |
Drug: Infliximab |
Phase II |
MedlinePlus related topics: Sarcoidosis
Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Safety and Efficacy of Infliximab (Remicade®) in Subjects with Chronic Sarcoidosis with Pulmonary Involvement
Expected Total Enrollment: 120
Study start: September 2003
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria
Exclusion Criteria
Location and Contact Information
More Information
U.S. National Library of Medicine, Contact NLM Customer Service | ||||||||||||||
National Institutes of Health, Department of Health & Human Services | ||||||||||||||
Copyright, Privacy, Accessibility, Freedom of Information Act |